New Study Raises Concerns Over Mifepristone Usage

A recent study has highlighted a troubling number of “severe adverse events” among women taking mifepristone—often referred to as “abortion drugs.” This research has evoked protests from the pro-life community, and experts are voicing their concerns about the implications of these findings for women in the U.S.

Katie Glenn Daniel, the legal director at SBA Pro Life America, expressed her shock at the disparities between the study’s findings and the information provided by the FDA regarding abortion drug labels. She noted that over 10% of women using abortion pills have sought emergency care, contrasting with the FDA’s claim of just 5%. This disparity indicates that many women have faced complications requiring hospital visits, yet the FDA has not gathered sufficient data on these situations. Daniel believes this research provides a much-needed perspective on the potential risks involved with these medications.

Mifepristone is described by the Mayo Clinic as a “pregnancy blocker,” typically used alongside misoprostol for terminating pregnancies or managing early miscarriages.

A study conducted by the Center for Ethics and Public Policy in Washington, D.C., revealed that the incidence of severe side effects associated with mifepristone usage is significantly higher—specifically, 22 times more so—than what is indicated on FDA-approved drug labels.

Approximately 11% of women reported experiencing serious adverse effects, such as infections and severe bleeding, after using mifepristone. Daniel emphasized that these reports draw from the largest existing dataset on the real-world application of mifepristone, painting a concerning picture of the risks these drugs pose to women’s health.

She added that patients are facing life-threatening issues and that the current telehealth prescriptions allow for medications to be ordered without necessary checks, undermining protective measures that in-person visits provide.

According to the Guttmacher Institute, mifepristone, which the Biden administration has sought to make more accessible, is the most widely used abortion medication in the U.S., accounting for about 63% of all abortions in 2023, up from 53% in 2020.

Daniel commented on the changing landscape of abortion drug prescriptions, noting concerns that telehealth options may enable individuals to circumvent important safeguards, as seen in some troubling cases.

Lastly, Daniel stated that the report is intended to encourage action from the upcoming administration to safeguard the well-being of women and fetuses. She also pointed out the data’s limitations, suggesting that the study only captured a portion of the affected population, particularly those with insurance.

Daniel concluded that this warrants further investigation by the FDA and public health agencies, as it underscores the need for a thorough discussion regarding the long-term safety of these drugs for women and their potential risks.